Beneficial effects of evacetrapib

Mearns, Bryony M.

doi:10.1038/nrcardio.2011.193

Research Highlight
Published: 29 November 2011

Pharmacotherapy

Beneficial effects of evacetrapib

Bryony M. Mearns

Nature Reviews Cardiology volume 9, page 6 (2012)Cite this article

475 Accesses
1 Citations
1 Altmetric
Metrics details

Subjects

Access through your institution

Buy or subscribe

No-one can deny the considerable benefit that statin-induced LDL-cholesterol (LDL-C) reduction has on patients with atherosclerosis. However, in attempts to reduce any residual risk in patients treated with statins, many clinicians are investigating the potential of also increasing HDL-cholesterol (HDL-C) levels. A trial by Stephen Nicholls and colleagues has provided promising results for the cholesteryl ester transfer protein (CETP) inhibitor evacetrapib.

Enrolled patients (aged ≥18 years) had triglyceride levels <400 mg/dl and either low HDL-C levels (<45 mg/dl for men or <50 mg/dl for women) or high LDL-C levels (100–190 mg/dl with 0–1 risk factors, 100–160 mg/dl with ≥2 risk factors and a 10-year coronary risk <10%, or 100–130 mg/dl with ≥2 risk factors and a 10-year coronary risk of 10–20%). The primary analysis included 382 patients randomly assigned to one of ten groups receiving various drug regimens for 12 weeks. All patients were followed up for 4–6 weeks after cessation of the study drug. Evacetrapib administration was generally well tolerated.

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Buy this article

Purchase on SpringerLink
Instant access to full article PDF

Buy now

Prices may be subject to local taxes which are calculated during checkout

ORIGINAL RESEARCH PAPER

Nicholls, S. J. et al. Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial. JAMA 306, 2099–2109 (2011)
Article CAS Google Scholar

Download references

Authors